Trial Profile
Feasibility of extracorporeal elimination of liposomal chemotherapeutics by double membrane plasmapheresis - CARL-Studie
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2019
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Vinorelbine
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CARL
- 08 Oct 2019 Status changed from recruiting to completed.
- 27 Dec 2012 Planned number of patients changed from 15 to 21 as reported by German Clinical Trials Register.
- 27 Dec 2012 Status changed from active, no longer recruiting to recruiting as reported by German Clinical Trials Register.